Epigenetic gestational age and trajectories of weight and height during childhood: a prospective cohort study.


Journal

Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977

Informations de publication

Date de publication:
16 12 2019
Historique:
received: 18 05 2019
accepted: 09 10 2019
entrez: 18 12 2019
pubmed: 18 12 2019
medline: 25 7 2020
Statut: epublish

Résumé

Differences between an individual's estimated epigenetic gestational age (EGA) and their actual gestational age (GA) are defined as gestational age acceleration (GAA). GAA is associated with increased birthweight and birth length. Whether these associations persist through childhood is yet to be investigated. We examined the association between GAA and trajectories of height and weight from birth to 10 years (n = 785) in a British birth cohort study, the Avon Longitudinal Study of Parents and Children (ALSPAC). EGA of participants was estimated using DNA methylation data from cord blood using a recently developed prediction model. GAA of participants, measured in weeks, was calculated as the residuals from a regression model of EGA on actual GA. Analyses were performed using linear spline multilevel models and adjusted for maternal age, maternal pre-pregnancy BMI, maternal smoking during pregnancy, and maternal education. In adjusted analyses, offspring with a one-week greater GAA were born on average 0.14 kg heavier (95% confidence interval (CI) 0.09, 0.19) and 0.55 cm taller (95% CI 0.33, 0.78) at birth. These differences in weight persisted up to approximately age 9 months but thereafter began to attenuate. From age 5 years onwards, the association between GAA and weight reversed such that GAA was associated with lower weight and this association strengthened with age (mean difference at age 10 years - 0.60 kg, 95% CI - 1.19, - 0.01). Differences in height persisted only up to age 9 months (mean difference at 9 months 0.15 cm, 95% CI - 0.09, 0.39). From age 9 months to age 10 years, offspring with a one-week greater GAA were of comparable height with those with no GAA (mean difference at age 10 years - 0.07 cm, 95% CI - 0.64, 0.50). Gestational age acceleration is associated with increased birth weight and length and these differences persist to age 9 months. From age 5 years onwards, the association of GAA and weight reverses such that by age 10 years, greater GAA is associated with lower childhood weight. Further work is required to examine whether the weight effects of GAA strengthen through adolescence and into early adulthood.

Sections du résumé

BACKGROUND
Differences between an individual's estimated epigenetic gestational age (EGA) and their actual gestational age (GA) are defined as gestational age acceleration (GAA). GAA is associated with increased birthweight and birth length. Whether these associations persist through childhood is yet to be investigated.
METHODS
We examined the association between GAA and trajectories of height and weight from birth to 10 years (n = 785) in a British birth cohort study, the Avon Longitudinal Study of Parents and Children (ALSPAC). EGA of participants was estimated using DNA methylation data from cord blood using a recently developed prediction model. GAA of participants, measured in weeks, was calculated as the residuals from a regression model of EGA on actual GA. Analyses were performed using linear spline multilevel models and adjusted for maternal age, maternal pre-pregnancy BMI, maternal smoking during pregnancy, and maternal education.
RESULTS
In adjusted analyses, offspring with a one-week greater GAA were born on average 0.14 kg heavier (95% confidence interval (CI) 0.09, 0.19) and 0.55 cm taller (95% CI 0.33, 0.78) at birth. These differences in weight persisted up to approximately age 9 months but thereafter began to attenuate. From age 5 years onwards, the association between GAA and weight reversed such that GAA was associated with lower weight and this association strengthened with age (mean difference at age 10 years - 0.60 kg, 95% CI - 1.19, - 0.01). Differences in height persisted only up to age 9 months (mean difference at 9 months 0.15 cm, 95% CI - 0.09, 0.39). From age 9 months to age 10 years, offspring with a one-week greater GAA were of comparable height with those with no GAA (mean difference at age 10 years - 0.07 cm, 95% CI - 0.64, 0.50).
CONCLUSIONS
Gestational age acceleration is associated with increased birth weight and length and these differences persist to age 9 months. From age 5 years onwards, the association of GAA and weight reverses such that by age 10 years, greater GAA is associated with lower childhood weight. Further work is required to examine whether the weight effects of GAA strengthen through adolescence and into early adulthood.

Identifiants

pubmed: 31842976
doi: 10.1186/s13148-019-0761-7
pii: 10.1186/s13148-019-0761-7
pmc: PMC6916215
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

194

Subventions

Organisme : Medical Research Council
ID : MC_UU_12013/4
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00011/7
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00011/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12013/8
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/I025263/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBI025751/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12013/6
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12013/9
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00011/5
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12013/3
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 102215/2/13/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12013/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M020894/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M014509/1
Pays : United Kingdom

Références

Semin Reprod Med. 2009 Sep;27(5):351-7
pubmed: 19711245
Int J Epidemiol. 2015 Aug;44(4):1181-90
pubmed: 25991711
Hum Mol Genet. 2016 Jan 1;25(1):191-201
pubmed: 26546615
PLoS One. 2013 May 17;8(5):e63812
pubmed: 23691101
PLoS One. 2012;7(3):e31821
pubmed: 22431966
BMC Med. 2016 Sep 28;14(1):147
pubmed: 27677312
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15538-43
pubmed: 25313081
Stat Med. 2002 Nov 15;21(21):3291-315
pubmed: 12375305
Am J Epidemiol. 1992 Jul 15;136(2):201-13
pubmed: 1415142
Int J Epidemiol. 2015 Aug;44(4):1388-96
pubmed: 25617346
Mol Cell. 2013 Jan 24;49(2):359-367
pubmed: 23177740
Aging (Albany NY). 2015 Dec;7(12):1198-211
pubmed: 26684672
Int J Epidemiol. 2017 Apr 1;46(2):549-558
pubmed: 28089957
Int J Epidemiol. 2013 Feb;42(1):111-27
pubmed: 22507743
Data Brief. 2019 Jan 19;23:103687
pubmed: 30847378
EBioMedicine. 2016 Feb 08;5:68-73
pubmed: 27077113
Int J Epidemiol. 2013 Feb;42(1):97-110
pubmed: 22507742
Stat Methods Med Res. 2016 Oct;25(5):1854-1874
pubmed: 24108269
Genome Biol. 2016 Oct 7;17(1):207
pubmed: 27717397
Hum Mol Genet. 2015 Apr 15;24(8):2201-17
pubmed: 25552657
Clin Epigenetics. 2017 Sep 15;9:100
pubmed: 28932320
Epigenomics. 2011 Dec;3(6):771-84
pubmed: 22126295
Int J Epidemiol. 2011 Oct;40(5):1215-26
pubmed: 21764769
Clin Epigenetics. 2018 Jun 27;10:86
pubmed: 29983833
Atherosclerosis. 2018 Jul;274:94-103
pubmed: 29753233
Atherosclerosis. 2018 Nov;278:190-196
pubmed: 30296724
Genome Biol. 2013;14(10):R115
pubmed: 24138928
Mol Psychiatry. 2018 Feb;23(2):422-433
pubmed: 27843151
Genome Biol. 2016 Oct 7;17(1):206
pubmed: 27717399

Auteurs

Harold D Bright (HD)

Bristol Medical School, Faculty of Health Sciences, University of Bristol, First Floor, 5 Tyndall Avenue, Bristol, BS8 1UD, UK. hb15624@bristol.ac.uk.

Laura D Howe (LD)

MRC Integrative Epidemiology Unit at the University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.

Jasmine N Khouja (JN)

MRC Integrative Epidemiology Unit at the University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.
School of Psychological Science at the University of Bristol, 12a Priory Road, Bristol, BS8 1TU, UK.

Andrew J Simpkin (AJ)

School of Mathematics, Statistics and Applied Mathematics, National University of Ireland, University Road, Galway, H91 TK33, Ireland.

Matthew Suderman (M)

MRC Integrative Epidemiology Unit at the University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.

Linda M O'Keeffe (LM)

MRC Integrative Epidemiology Unit at the University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH